Review
Copyright ©The Author(s) 2023.
World J Stem Cells. Feb 26, 2023; 15(2): 16-30
Published online Feb 26, 2023. doi: 10.4252/wjsc.v15.i2.16
Table 1 Minimal criteria for defining mesenchymal stem cells
Morphology, growth conditions
Spindle-shaped (fibroblast-like), adherent
Specific surface markersCD73+, CD90+, CD105+, CD11b-, CD14-, CD19-, CD45-, CD79α-, MHC-II, HLA-DR-
Differentiation potentialAdipogenic, chondrogenic, osteogenic
Table 2 Selected clinical trials of mesenchymal stem cell-based therapy in ischemic diseases
Disorder
Ref.
Trial number (acronym)
Type of transplant and stem cell source
Results
Myocardial infarctionHare et al[36], 2009NCT00114452Allogenic BM-MSCsNo tumorogenicity, no arrythomogenicity
Myocardial infarctionHoutgraaf et al[37], 2012NCT00442806 (APOLLO)Autologous AT-MSCsNo adverse effects, decreased: Scar tissue; increased: Perfusion
Myocardial infarctionGao et al[122], 2015NCT01291329Allogenic WJ-MSCsIncreased: Ejection fraction; decreased: Heart perfusion
Chronic ischemic cardiomyopathyHare et al[123], 2012NCT01087996 (POSEIDON)Allogenic vs autologous BM-MSCsIncreased: Ejection fraction; decreased: Scar tissue
Chronic ischemic cardiomyopathyKarantalis et al[124], 2014NCT00587990 (PROMETHEUS)Autologous BM-MSCsLocal; increased: Contraction; decreased: Scar tissue
Chronic ischemic cardiomyopathyPerin et al[125], 2014NCT00426868 (PRECISE)Autologous AT-MSCsIncreased: Left ventricular mass; increased: Contractility; increased: Perfusion
Chronic ischemic cardiomyopathyBartunek et al[126], 2013NCT00810238 (C-CURE)Preconditioned autologous BM-MSCsIncreased: Ejection fraction
Chronic ischemic cardiomyopathyBartolucci et al[118], 2017NCT01739777 (RIMECARD)Allogenic UC-MSCsIncreased: Ejection fraction
Ischemic heart failureTeerlink et al[127], 2017NCT01768702 (CHART-1)Autologous BM-MSCsLeft ventricular reverse remodelling, increased: Left ventricular volume
Critical limb ischemiaWijnand et al[128], 2018NCT03042572 (SAIL)Allogenic BM-MSCsSafety, decreased: Pain rest
Critical limb ischemiaNorgren et al[129], 2018NCT01732822 (EUCLID)Allogeneic placental-derived MSCsIncreased: Amputation-free survival; decreased: Pain rest; increased: Tissue perfusion
Critical limb ischemiaGupta et al[130], 2013NCT00883870Allogenic BM-MSCsDecreased: Pain rest; increased: Ankle systolic pressure; increased: Ulcer healing
Ischemic strokeSteinberg et al[131], 2016NCT01287936Modified BM-MSCsIncreased: Motor functions (ESS, NIHSS, Fugle-Meyer scales)
Ischemic strokeLevy et al[132], 2019NCT01297413Allogenic BM-MSCsIncreased: Barthel index
Ischemic strokeSavitz et al[133], 2019NCT01273337 (RECOVER-Stroke)Autologous BM-MSCsSafety
Ischemic strokeLaskowitz et al[134], 2018NCT03004976Allogenic UCB-MSCsSafety and feasibility
Ischemic strokeJaillard et al[135], 2020NCT00875654Autologous BM-MSCsIncreased: Motor functions (NIHSS, Fugle-Meyer scales)